Yonghao Zhao

Yonghao Zhao

Auto-generated profile, based on publicly available information

Yonghao Zhao

Affiliations Chengdu Kanghong Pharmaceutical Group Company Limited, Chengdu, China, Therapeutic Proteins Key Laboratory of Sichuan Provincial, Chengdu, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PRPengfei Ren
Pengfei Ren
MGMenglong Guan
Menglong Guan
JTJiao Tang
Jiao Tang
SYShijun Yin
Shijun Yin
LQLu Qi
Lu Qi
YZYonghao Zhao
Yonghao Zhao
Antibody–drug conjugates (ADC) that utilize DNA topoisomerase I inhibitors, such as deruxtecan and SN-38, have significantly enhanced the efficacy of cancer treatment. However, the development of more effective ADCs to combat drug-resistant tumors remains a critical challenge. ADCs covalently link the topoisomerase I inhibitor exatecan and the RNA polymerase II inhibitor triptolide to the same antibody, thereby establishing a dual-killing mechanism against tumor cells. Through optimization of the linker design, this dual-payload ADC achieved precise drug delivery in vivo. Specifically, triptolide is initially released to downregulate the expression of the stress response protein heat shock protein 70 and the efflux pump P-glycoprotein in tumor cells, thereby significantly enhancing drug sensitivity and effectively overcoming resistance, followed by gradual exatecan release, further inhibiting tumor cell proliferation and survival. Experimental results demonstrated that this dual-payload ADC exhibits significant antitumor activity in both in vitro cell models and in vivo xenograft models, including cell line–derived xenograft and patient-derived xenograft models, successfully addressing the challenge of drug resistance encountered in traditional monotherapy. Additionally, non-Good Laboratory Practice–compliant toxicity studies have confirmed the favorable safety profile of this ADC. In summary, this study provides an innovative strategy for overcoming tumor resistance, demonstrating substantial potential for clinical translation, and offering promising therapeutic outcomes and prognosis for patients with cancer.

2 April 2026
Verified
Other
Open access
PRPengfei Ren
Pengfei Ren
MGMenglong Guan
Menglong Guan
JTJiao Tang
Jiao Tang
SYShijun Yin
Shijun Yin
LQLu Qi
Lu Qi
YZYonghao Zhao
Yonghao Zhao
Antibody–drug conjugates (ADC) that utilize DNA topoisomerase I inhibitors, such as deruxtecan and SN-38, have significantly enhanced the efficacy of cancer treatment. However, the development of more effective ADCs to combat drug-resistant tumors remains a critical challenge. ADCs covalently link the topoisomerase I inhibitor exatecan and the RNA polymerase II inhibitor triptolide to the same antibody, thereby establishing a dual-killing mechanism against tumor cells. Through optimization of the linker design, this dual-payload ADC achieved precise drug delivery in vivo. Specifically, triptolide is initially released to downregulate the expression of the stress response protein heat shock protein 70 and the efflux pump P-glycoprotein in tumor cells, thereby significantly enhancing drug sensitivity and effectively overcoming resistance, followed by gradual exatecan release, further inhibiting tumor cell proliferation and survival. Experimental results demonstrated that this dual-payload ADC exhibits significant antitumor activity in both in vitro cell models and in vivo xenograft models, including cell line–derived xenograft and patient-derived xenograft models, successfully addressing the challenge of drug resistance encountered in traditional monotherapy. Additionally, non-Good Laboratory Practice–compliant toxicity studies have confirmed the favorable safety profile of this ADC. In summary, this study provides an innovative strategy for overcoming tumor resistance, demonstrating substantial potential for clinical translation, and offering promising therapeutic outcomes and prognosis for patients with cancer.

11 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JZJingxin Zeng
Jingxin Zeng
WSWenwen Shang
Wenwen Shang
PRPengfei Ren
Pengfei Ren
XKXiao Ke
Xiao Ke
YZYonghao Zhao
Yonghao Zhao
SJShuang xiao Jiang
Shuang xiao Jiang
Objective: Neovascular age-related macular degeneration (nAMD) is characterized by pathological neovascularization in the macula, leading to irreversible central vision loss. This study aimed to evaluate cytokine profiles in the aqueous humor of nAMD patients and explore correlation between specific cytokines, clinical characteristics, and retinal morphological features. Methods: Our protocol was registered on Chinese Clinical Trial Registry (ChiCTR) under registration number ChiCTR2500106190 and approved by the Biomedical Research Ethics Committee of West China Hospital, Sichuan University (ID: 20231375). A total of 94 patients with nAMD and 34 cataract patients as the control group were enrolled. Aqueous humor samples were collected before anti-VEGF treatment or cataract surgery, and analyzed using cytometric bead array (CBA) for cytokines (MCP-1, ICAM-1, VCAM-1, CA-1, β-FGF, PPK/PK, and VEGF). Retinal structural biomarkers were assessed using optical coherence tomography (OCT), with statistical analysis performed to evaluate correlations between cytokine levels and retinal morphology. Results: Compared to cataract patients, nAMD patients exhibited elevated levels of CA-1, PPK/PK, ICAM-1, VCAM-1, and MCP-1 (P < 0.05). Baseline best-corrected visual acuity (BCVA) was reduced in nAMD patients with intraretinal fluid (IRF) or pigmentation compared to those without (P < 0.05). Visit BCVA also deteriorated in patients with fibrosis (P < 0.05). Additionally, central foveal thickness (CTR) was significantly thinner in patients with PED or SRF (P < 0.05). Visit BCVA demonstrated positive correlations with baseline BCVA (r = 0.689, P < 0.001). In contrast, the presence of fibrosis and elevated MCP-1 concentration was associated with a poorer visual outcome. In correlation analysis, β-FGF exhibited a negative correlation with CA-1, PPK, ICAM-1. VCAM-1 and MCP-1. Conclusion: In this cross-sectional study, the presence of IRF was significantly associated with reduced BCVA in nAMD patients. Baseline BCVA emerged as a critical predictor of visual prognosis in nAMD. Notably, retinal fibrosis development and elevated MCP-1 level linked to worse clinical outcomes, underscoring their potential as therapeutic targets. While recent anti-VEGF injections decreased VEGF levels in aqueous humor of nAMD patients, the impact of these agents on other cytokines remain unclear, suggesting a need for adjunct therapies to address multifaceted pathogenic pathways.

2 April 2026
Verified
Other
Open access
PRPengfei Ren
Pengfei Ren
MGMenglong Guan
Menglong Guan
JTJiao Tang
Jiao Tang
SYShijun Yin
Shijun Yin
LQLu Qi
Lu Qi
YZYonghao Zhao
Yonghao Zhao
This supplemental file contains three core parts: Supplemental Materials and Methods, Supplemental Figure S1, and Supplemental Figure S2. Supplemental Materials and Methods Details the experimental protocols and technical parameters of all in vitro, in vivo, and analytical experiments in this study, laying a foundation for the reproducibility of the research. Supplemental Figure S1 Presents the amino acid sequences of Datopotamab, Patritumab and hRS7 (sacituzumab), along with the drug-antibody ratio (DAR) distribution data of the dual-payload ADC hRS7-E+T. Supplemental Figure S2: Shows the key mechanistic details of how the dual-payload ADC hRS7-E+T acts on target cells through different pathways.